CTX-8371
Phase 1Small molecule
CTX-8371 is one of 38 small molecule programs targeting Non-Small Cell Lung Cancer. It is currently in Phase 1.
1
Indications
1
Total Trials
1
Active Trials
37
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
414 competitors in Non-Small Cell Lung Cancer
#DrugCompanyPhaseTrials
1Nano-Crystalline Megestrol Acetate
Changchun GeneScience Pharmaceutical Co., Ltd.Phase 3
Carboplatin/paclitaxel
AstraZenecaPhase 3
Consolidative Therapy
SSun Yat-sen University
Phase 3
Remeron
OOrganon and Co
Preclinical
Ftorafur
TThe First Affiliated Hospital with Nanjing Medical University
Preclinical
Vibramycin
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Preclinical
Treatment
GSKPreclinical
Aqupla
Jiangsu Simcere Pharmaceutical Co., Ltd.Preclinical
PD-1 Inhibitors
BBioNTech US Inc.
Preclinical
Pyrotinib Maleate
AstraZenecaPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for CTX-8371. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 1[1]
- Company
- CCompass Therapeutics